# Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

> **NCT02156336** · PHASE4 · TERMINATED · sponsor: **Horizons International Peripheral Group** · enrollment: 4 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02156336
- **Lead sponsor:** Horizons International Peripheral Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2017-02-08
- **Final completion:** 2017-02-08
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Not enough patients met study criteria for enrollment.
- **Last updated:** 2017-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156336, "Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02156336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*